» Articles » PMID: 31081218

Integrative Analyses of Triple Negative Dysregulated Transcripts Compared with Non-triple Negative Tumors and Their Functional and Molecular Interactions

Overview
Journal J Cell Physiol
Specialties Cell Biology
Physiology
Date 2019 May 14
PMID 31081218
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Triple-negative (TN) tumors are a subtype of breast cancer with aggressive behaviors and limited targeted therapies. Microarray studies were not concerned with interactions and functional relations of dysregulated transcripts. Here, we aimed to conduct integrative strategy to analyze gene and miRNA available microarray data as well as bioinformatic analyses to catch a more inclusive picture of pivotal dysregulated transcripts and their interactions in TN tumors. Several online datasets and offline bioinformatic tools were used to detect differentially expressed (DE) transcripts, both protein and nonprotein coding, in TN compared with non-TN tumors and their functional and molecular interactions. Sixteen upregulated and 58 downregulated genes with a log fold change higher or equal to | 2 | were identified, including nine transcription factors. Coexpression network revealed EN1 as a hub gene, moreover Kaplan-Meier plotter survival analysis indicated that it was an appropriate prognostic marker for TN patients with breast cancer. Functional annotation analysis of protein-protein interaction network showed FOXM1 as an upexpressed and ESR1 as a downexpressed hub genes are suitable targets as far as antitumor protein therapy is concerned in TN breast cancers. The consensus analysis of two microRNA datasets revealed seven DE miRNAs. The gene-transcriptional factor (TF)-miRNA network revealed mir-135b and mir-29b are the hub nodes and involved in feedback loops with GATA3. This study suggests that dysregulated TFs and miRNAs have pivotal roles in regulation of TN oncotranscriptomic profile and might become both biomarkers and therapeutic targets.

Citing Articles

Machine learning-guided differential gene expression analysis identifies a highly-connected seven-gene cluster in triple-negative breast cancer.

Ghazal H, El-Absawy E, Ead W, Hasan M Biomedicine (Taipei). 2025; 14(4):15-35.

PMID: 39777114 PMC: 11703398. DOI: 10.37796/2211-8039.1467.


Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches.

Pastena P, Perera H, Martinino A, Kartsonis W, Giovinazzo F Int J Mol Sci. 2024; 25(5).

PMID: 38473804 PMC: 10931553. DOI: 10.3390/ijms25052559.


Evaluation of Circ_0000977-Mediated Regulatory Network in Breast Cancer: A Potential Discriminative Biomarker for Triple-Negative Tumors.

Darbeheshti F, Mansoori Y, Azizi-Tabesh G, Zolfaghari F, Kadkhoda S, Rasti A Biochem Genet. 2023; 61(4):1487-1508.

PMID: 36645554 DOI: 10.1007/s10528-023-10331-x.


RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis.

Li Z, Su P, Ding Y, Gao H, Yang H, Li X Cell Commun Signal. 2022; 20(1):164.

PMID: 36280829 PMC: 9590148. DOI: 10.1186/s12964-022-00963-8.


Circular RNA-associated ceRNA network involved in HIF-1 signalling in triple-negative breast cancer: circ_0047303 as a potential key regulator.

Darbeheshti F, Mahdiannasser M, Noroozi Z, Firoozi Z, Mansoori B, Daraei A J Cell Mol Med. 2021; 25(24):11322-11332.

PMID: 34791795 PMC: 8650046. DOI: 10.1111/jcmm.17066.